Blog

Nathan A. Pennell: Pralsetinib development outside the US and China also stopped

Photo from Nathan A. Pennell/X

Jan 13, 2024, 10:04

Nathan A. Pennell: Pralsetinib development outside the US and China also stopped

Nathan A. Pennell, Co-Director of the Cleveland Clinic Lung Cancer Program, shared a post by EGFR Resisters on X/Twitter:

“Oh man, pralsetinib (for RET+ tumors) development outside the US and China also stopped. Hope this gets resumed with new partners.”

Quoting EGFR Resisters’s post:

“Blueprint Medicines issued press release: “Discontinue further investment in the early clinical stage therapies BLU 945 and 451 for EGFR Non-Small Cell Lung Cancer and explore strategic options including potential outlicensing” Blu-945 and Blu-451 clinical trials will close.”

Read further.

Source: Nathan A. Pennell/X and EGFR Resisters/X

Blu-451 Blu-945 Blueprint Medicines cancer Cleveland Clinic EGFR Resisters Nathan A.Pennell non small cell lung cancer NSCLC OncoDaily Oncology pralsetinib RET

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage